Is Dynavax Technologies Stock a Good Investment?
Dynavax Technologies Investment Advice | DVAX |
- Examine Dynavax Technologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dynavax Technologies' leadership team and their track record. Good management can help Dynavax Technologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Dynavax Technologies' business and its evolving consumer preferences.
- Compare Dynavax Technologies' performance and market position to its competitors. Analyze how Dynavax Technologies is positioned in terms of product offerings, innovation, and market share.
- Check if Dynavax Technologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dynavax Technologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dynavax Technologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dynavax Technologies is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Dynavax Technologies Stock
Researching Dynavax Technologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dynavax Technologies was currently reported as 5.19. The company had not issued any dividends in recent years. Dynavax Technologies had 1:10 split on the 10th of November 2014.
To determine if Dynavax Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dynavax Technologies' research are outlined below:
| The company reported the previous year's revenue of 232.28 M. Net Loss for the year was (6.39 M) with profit before overhead, payroll, taxes, and interest of 448.22 M. | |
| Dynavax Technologies has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Where are the Opportunities in - Stock Traders Daily |
Dynavax Technologies Quarterly Liabilities And Stockholders Equity |
|
Dynavax Technologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dynavax Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dynavax Technologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Dynavax Technologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Dynavax Technologies' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-22 | 2023-12-31 | -0.01 | 0.0016 | 0.0116 | 116 | ||
2024-08-06 | 2024-06-30 | 0.06 | 0.08 | 0.02 | 33 | ||
2021-05-06 | 2021-03-31 | -0.02 | 0.01 | 0.03 | 150 | ||
2024-05-08 | 2024-03-31 | -0.02 | -0.07 | -0.05 | 250 | ||
2023-05-02 | 2023-03-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2021-08-04 | 2021-06-30 | -0.04 | 0.02 | 0.06 | 150 | ||
2016-08-05 | 2016-06-30 | -0.68 | -0.75 | -0.07 | 10 | ||
2016-05-09 | 2016-03-31 | -0.63 | -0.7 | -0.07 | 11 |
Know Dynavax Technologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dynavax Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dynavax Technologies backward and forwards among themselves. Dynavax Technologies' institutional investor refers to the entity that pools money to purchase Dynavax Technologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Great Point Partners Llc | 2024-06-30 | 2.4 M | Blair William & Co | 2024-06-30 | 2.4 M | Renaissance Technologies Corp | 2024-09-30 | 2.3 M | Tang Capital Management Llc | 2024-09-30 | 1.9 M | Millennium Management Llc | 2024-06-30 | 1.6 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.4 M | Mizuho Markets Americas Llc | 2024-09-30 | 1.4 M | Fisher Asset Management, Llc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Blackrock Inc | 2024-06-30 | 21.9 M | Deep Track Capital, Lp | 2024-09-30 | 12.5 M |
Dynavax Technologies' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.63 B.Market Cap |
|
Dynavax Technologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Determining Dynavax Technologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Dynavax Technologies is a good buy. For example, gross profit margin measures Dynavax Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dynavax Technologies' profitability and make more informed investment decisions.
Dynavax Technologies' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Dynavax Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dynavax Technologies. Check Dynavax Technologies' Beneish M Score to see the likelihood of Dynavax Technologies' management manipulating its earnings.
Evaluate Dynavax Technologies' management efficiency
Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 21.4 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.83 | 5.07 | |
| Tangible Book Value Per Share | 4.82 | 5.06 | |
| Enterprise Value Over EBITDA | 197.22 | 207.08 | |
| Price Book Value Ratio | 2.89 | 4.48 | |
| Enterprise Value Multiple | 197.22 | 207.08 | |
| Price Fair Value | 2.89 | 4.48 | |
| Enterprise Value | 356.6 M | 317 M |
Evaluating the management effectiveness of Dynavax Technologies allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dynavax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.342 |
Basic technical analysis of Dynavax Stock
As of the 24th of November, Dynavax Technologies shows the Mean Deviation of 1.76, coefficient of variation of 1396.11, and Downside Deviation of 2.31. Dynavax Technologies technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dynavax Technologies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dynavax Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dynavax Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dynavax Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dynavax Technologies' Outstanding Corporate Bonds
Dynavax Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dynavax Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dynavax bonds can be classified according to their maturity, which is the date when Dynavax Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Dynavax Technologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Dynavax Technologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0618 | |||
| Market Risk Adjusted Performance | 0.1582 | |||
| Mean Deviation | 1.76 | |||
| Semi Deviation | 2.13 | |||
| Downside Deviation | 2.31 | |||
| Coefficient Of Variation | 1396.11 | |||
| Standard Deviation | 2.45 | |||
| Variance | 6.0 | |||
| Information Ratio | 0.0183 | |||
| Jensen Alpha | 0.0306 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0194 | |||
| Treynor Ratio | 0.1482 | |||
| Maximum Drawdown | 17.05 | |||
| Value At Risk | (2.93) | |||
| Potential Upside | 3.69 | |||
| Downside Variance | 5.34 | |||
| Semi Variance | 4.55 | |||
| Expected Short fall | (1.93) | |||
| Skewness | 0.058 | |||
| Kurtosis | 3.43 |
| Risk Adjusted Performance | 0.0618 | |||
| Market Risk Adjusted Performance | 0.1582 | |||
| Mean Deviation | 1.76 | |||
| Semi Deviation | 2.13 | |||
| Downside Deviation | 2.31 | |||
| Coefficient Of Variation | 1396.11 | |||
| Standard Deviation | 2.45 | |||
| Variance | 6.0 | |||
| Information Ratio | 0.0183 | |||
| Jensen Alpha | 0.0306 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0194 | |||
| Treynor Ratio | 0.1482 | |||
| Maximum Drawdown | 17.05 | |||
| Value At Risk | (2.93) | |||
| Potential Upside | 3.69 | |||
| Downside Variance | 5.34 | |||
| Semi Variance | 4.55 | |||
| Expected Short fall | (1.93) | |||
| Skewness | 0.058 | |||
| Kurtosis | 3.43 |
Consider Dynavax Technologies' intraday indicators
Dynavax Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dynavax Technologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dynavax Technologies Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 24th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 18th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Dynavax Stock media impact
Far too much social signal, news, headlines, and media speculation about Dynavax Technologies that are available to investors today. That information is available publicly through Dynavax media outlets and privately through word of mouth or via Dynavax internal channels. However, regardless of the origin, that massive amount of Dynavax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dynavax Technologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dynavax Technologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dynavax Technologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dynavax Technologies alpha.
Dynavax Technologies Corporate Management
| David Novack | Sr. VP of Operations and Quality | Profile | |
| Eric Frings | Site VP | Profile | |
| Robert MD | Medical Development | Profile | |
| Donn Casale | Senior Officer | Profile | |
| Nicole Arndt | Sr Relations | Profile |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.